SMARCB1 and epithelioid sarcoma: Based on this promising preclinical data, an ongoing phase II clinical trial of tazemetostat in patients with advanced epithelioid sarcoma with loss of INI1/SMARCB1 will evaluate the clinical relevance of targeting this epigenetic axis in patients with SCCOTH (14).